FIRST FINANCIAL BANCORP. Common Shares, without par value UNDERWRITING AGREEMENT
Exhibit
1.1
Execution
Version
5,614,200
FIRST
FINANCIAL BANCORP.
Common
Shares, without par value
January
27, 2010
Barclays
Capital Inc.
As
Representative of the several
Underwriters
named in Schedule 1 attached hereto
000
Xxxxxxx Xxxxxx
Xxx Xxxx,
Xxx Xxxx 00000
Ladies
and Gentlemen:
First
Financial Bancorp., an Ohio corporation (the “Company”), proposes, subject
to the terms and conditions stated herein, to issue and sell to the several
underwriters (the “Underwriters”) named in Schedule 1 attached
to this agreement (this “Agreement”) an aggregate of
5,614,200 common shares (the “Firm Shares”), without par
value, of the Company (the “Common Shares”). In
addition, the Company proposes to grant to the several Underwriters an option to
purchase up to 757,917 additional Common Shares solely to cover over-allotments
on the terms and for the purposes set forth in Section 2 (the “Option
Shares”). The Firm Shares and the Option Shares, if purchased,
are hereinafter collectively called the “Shares.” This is to
confirm the agreement concerning the purchase of the Shares from the Company by
the Underwriters.
1.
Representations, Warranties
and Agreements of the Company. The
Company represents, warrants and agrees that:
(a) A
registration statement on Form S-3 (File No. 333-153751) relating to the Shares
has: (i) been prepared by the Company in conformity with the requirements
of the Securities Act of 1933, as amended (the “Securities Act”), and the
rules and regulations (the “Rules and Regulations”) of the
Securities and Exchange Commission (the “Commission”) thereunder;
(ii) been filed with the Commission under the Securities Act; and
(iii) become effective under the Securities Act. Copies of such
registration statement and any amendment thereto have been delivered or made
available by the Company to you as the representative (the “Representative”) of the
Underwriters. As used in this Agreement:
(i)
“Applicable Time”
means 5:30 p.m. (New York City time) on January 27, 2010;
(ii) “Effective Date” means any date
as of which any part of such registration statement relating to the Shares
became, or is deemed to have become, effective under the Securities Act in
accordance with the Rules and Regulations;
(iii) “Issuer Free Writing
Prospectus” means each “free writing prospectus” (as defined in Rule 405
of the Rules and Regulations) prepared by or on behalf of the Company or used or
referred to by the Company in connection with the offering of the
Shares;
(iv) “Preliminary Prospectus” means
any preliminary prospectus relating to the Shares included in such registration
statement or filed with the Commission pursuant to Rule 424(b) of the Rules and
Regulations, including any preliminary prospectus supplement thereto relating to
the Shares;
(v) “Pricing Disclosure Package”
means, as of the Applicable Time, the most recent Preliminary Prospectus,
together with the information included in Schedule 3 hereto and
each Issuer Free Writing Prospectus filed or used by the Company on or before
the Applicable Time, other than a road show that is an Issuer Free Writing
Prospectus under Rule 433 of the Rules and Regulations;
(vi) “Prospectus” means the final
prospectus relating to the Shares, including any prospectus supplement thereto
relating to the Shares, as filed with the Commission pursuant to Rule 424(b) of
the Rules and Regulations; and
(vii) “Registration Statement” means,
collectively, the various parts of such registration statement, each as amended
as of the Effective Date for such part, including any Preliminary Prospectus or
the Prospectus and all exhibits to such registration statement.
Any
reference to any Preliminary Prospectus or the Prospectus shall be deemed to
refer to and include any documents incorporated by reference therein under the
Securities Act as of the date of such Preliminary Prospectus or the Prospectus,
as the case may be. Any reference to the “most recent Preliminary
Prospectus” shall be deemed to refer to the latest Preliminary Prospectus
included in the Registration Statement or filed pursuant to Rule 424(b) prior to
or on the date hereof (including, for purposes hereof, any documents
incorporated by reference therein prior to or on the date
hereof). Any reference to any amendment or supplement to any
Preliminary Prospectus or the Prospectus shall be deemed to refer to and include
any document filed under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), after
the date of such Preliminary Prospectus or the Prospectus, as the case may be,
and incorporated by reference in such Preliminary Prospectus or the Prospectus,
as the case may be; and any reference to any amendment to the Registration
Statement shall be deemed to include any annual report of the Company on Form
10-K filed with the Commission pursuant to Section 13(a) or 15(d) of the
Exchange Act after the Effective Date that is incorporated by reference in the
Registration Statement. The Commission has not issued any order
preventing or suspending the use of any Preliminary Prospectus or the Prospectus
or suspending the effectiveness of the Registration Statement, and no proceeding
or examination for such purpose has been instituted or threatened by the
Commission.
2
(b) The
Company was not at the time of initial filing of the Registration Statement and
at the earliest time thereafter that the Company or another offering participant
made a bona fide offer
(within the meaning of Rule 164(h)(2) of the Rules and Regulations) of the
Shares, is not on the date hereof and will not be on the applicable Delivery
Date an “ineligible issuer” (as defined in Rule 405 of the Rules and
Regulations). The Company has been since the time of initial filing
of the Registration Statement and continues to be eligible to use Form S-3 for
the offering of the Shares.
(c) The
Registration Statement conformed and will conform in all material respects on
the Effective Date and on the applicable Delivery Date, and any amendment to the
Registration Statement filed after the date hereof will conform in all material
respects when filed, to the requirements of the Securities Act and the Rules and
Regulations. The most recent Preliminary Prospectus conformed, and
the Prospectus will conform, in all material respects when filed with the
Commission pursuant to Rule 424(b) and on the applicable Delivery Date to the
requirements of the Securities Act and the Rules and Regulations. The
documents incorporated by reference in any Preliminary Prospectus or the
Prospectus conformed, and any further documents so incorporated will conform,
when filed with the Commission, in all material respects to the requirements of
the Exchange Act or the Securities Act, as applicable, and the rules and
regulations of the Commission thereunder.
(d) The
Registration Statement did not, as of the Effective Date, contain an untrue
statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein not misleading; provided, that no
representation or warranty is made as to information contained in or omitted
from the Registration Statement in reliance upon and in conformity with written
information furnished to the Company through the Representative by or on behalf
of any Underwriter specifically for inclusion therein, which information is
specified in Section 8(e).
(e) The
Prospectus will not, as of its date and on the applicable Delivery Date, contain
an untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading; provided, that no
representation or warranty is made as to information contained in or omitted
from the Prospectus in reliance upon and in conformity with written information
furnished to the Company through the Representative by or on behalf of any
Underwriter specifically for inclusion therein, which information is specified
in Section 8(e).
(f) The
documents incorporated by reference in any Preliminary Prospectus or the
Prospectus did not, and any further documents filed and incorporated by
reference therein will not, when filed with the Commission, contain an untrue
statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading.
3
(g) The
Pricing Disclosure Package did not, as of the Applicable Time, contain an untrue
statement of a material fact or omit to state a material fact necessary to make
the statements therein, in the light of the circumstances under which they were
made, not misleading; provided, that no
representation or warranty is made as to information contained in or omitted
from the Pricing Disclosure Package in reliance upon and in conformity with
written information furnished to the Company through the Representative by or on
behalf of any Underwriter specifically for inclusion therein, which information
is specified in Section 8(e).
(h) Each
Issuer Free Writing Prospectus (including, without limitation, any road show
that is a free writing prospectus under Rule 433), when considered together with
the Pricing Disclosure Package as of the Applicable Time, did not contain an
untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading.
(i)
Each Issuer Free Writing Prospectus conformed or will
conform in all material respects to the requirements of the Securities Act and
the Rules and Regulations on the date of first use, and the Company has complied
with any filing requirements applicable to such Issuer Free Writing Prospectus
pursuant to the Rules and Regulations. The Company has not made any
offer relating to the Shares that would constitute an Issuer Free Writing
Prospectus without the prior written consent of the
Representative. The Company has retained in accordance with the Rules
and Regulations all Issuer Free Writing Prospectuses that were not required to
be filed pursuant to the Rules and Regulations.
(j)
Since the Effective Date, no event has occurred that should have
been set forth in a supplement or amendment to the Registration Statement, the
Prospectus or any Issuer Free Writing Prospectus that has not been so set
forth.
(k) Ernst
& Young LLP, the independent registered public accounting firm that
certified certain financial statements of the Company and its consolidated
subsidiaries, whose report appears in the most recent Preliminary Prospectus or
is incorporated by reference therein and who have delivered the initial letter
referred to in Section 7(g) hereof, is an independent registered public
accounting firm as required by the Securities Act and the Rules and
Regulations. With respect to the Company, to the Company’s knowledge,
Ernst & Young LLP has not been in violation of the auditor independence
requirements of the Xxxxxxxx-Xxxxx Act of 2002 (“Xxxxxxxx-Xxxxx Act”) and the
related Rules and Regulations.
(l) The
historical financial statements (including the related notes and supporting
schedules) included or incorporated by reference in the most recent Preliminary
Prospectus comply as to form in all material respects with the requirements of
Regulation S-X under the Securities Act and present fairly the financial
condition, results of operations and cash flows of the entities purported to be
shown thereby at the dates and for the periods indicated and have been prepared
in conformity with accounting principles generally accepted in the United States
applied on a consistent basis throughout the periods involved (except as
otherwise noted therein). To the extent applicable, all disclosures
contained in the Registration Statement or the Prospectus regarding “non-GAAP
financial measures” (as such term is defined by the rules and regulations of the
Commission) comply with Regulation G of the Exchange Act, the rules and
Regulations of the Commission under the Exchange Act and Item 10 of Regulation
S-K under the Securities Act, as applicable.
4
(m) Since
the date of the most recent financial statements of the Company included or
incorporated by reference in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, except as otherwise stated therein, (i) there
has been no material adverse change in the condition, financial or otherwise, or
in the earnings, business affairs or business prospects of the Company and its
subsidiaries taken as a whole, whether or not arising in the ordinary course of
business, and there has been no effect with respect to the Company and its
subsidiaries taken as a whole, which would prevent, or be reasonably likely to
prevent, the Company from consummating the transaction contemplated by this
Agreement (a “Material Adverse
Effect”), (ii) there have been no transactions entered into by the
Company or any of its subsidiaries, other than those in the ordinary course of
business, which are material with respect to the Company and its subsidiaries
taken as a whole, (iii) the Company and its subsidiaries, taken as a whole, have
not incurred any material liability or obligation, indirect, direct or
contingent, not in the ordinary course of business and (iv) except for
dividends on the Common Shares in amounts per share that are consistent with
past practice and on the Company’s Fixed Rate Cumulative Perpetual Preferred
Stock, Series A, without par value, there has been no dividend or
distribution of any kind declared, paid or made by the Company on any class of
its capital stock.
(n) The
Company is a registered bank holding company under the Bank Holding Company Act
of 1956, as amended, and has been duly organized and is validly existing as a
corporation in good standing under the laws of the State of Ohio and has the
power and authority (corporate and otherwise) to own, lease and operate its
properties, to conduct its business as described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus and to enter into and perform
its obligations under this Agreement. The Company is duly qualified
as a foreign corporation to transact business and is in good standing in each
other jurisdiction in which such qualification is required, whether by reason of
the ownership or leasing of property or the conduct of business, except where
the failure so to qualify or to be in good standing would not, individually or
in the aggregate, reasonably be expected to result in a Material Adverse
Effect.
5
(o) Each
“significant subsidiary” of the Company (as such term is defined in Rule 1-02 of
Regulation S-X) (each a “Significant Subsidiary” and, collectively,
the “Significant
Subsidiaries”) (i) has been duly organized and is validly existing
as a corporation, limited liability company, limited partnership, trust company,
statutory business trust or national banking association in good standing under
the laws of its respective jurisdiction of incorporation or organization,
(ii) has the power and authority (corporate and otherwise) to own, lease
and operate its properties and to conduct its business as described in the
Pricing Disclosure Package and the Prospectus and (iii) is duly qualified
as a foreign organization to transact business and is in good standing in each
jurisdiction in which such qualification is required, whether by reason of the
ownership or leasing of property or the conduct of business, except in the case
of clauses (ii) or (iii) where the failure to qualify or to be in good
standing would not, individually or in the aggregate, result in a Material
Adverse Effect. Except as otherwise disclosed in the Pricing
Disclosure Package and Prospectus, all of the issued and outstanding capital
stock or other equity interests of each such Significant Subsidiary that is a
corporation has been duly authorized and validly issued, is fully paid and,
except as provided in 12 U.S.C. Section 55, non-assessable. All of
the issued and outstanding shares of capital stock or other equity interests of
each such Significant Subsidiary have been duly authorized and validly issued,
are fully paid and non-assessable and are owned by the Company, directly or
through subsidiaries, free and clear of any security interest, mortgage, pledge,
lien, encumbrance, or claim of equity. None of the outstanding shares
of capital stock or other equity interest of any Significant Subsidiary was
issued in violation of the preemptive or similar rights of any security holder
or equity holder of such Significant Subsidiary. The only Significant
Subsidiaries of the Company are the Significant Subsidiaries listed on Schedule 4
hereto.
(p) The
authorized, issued and outstanding capital stock of the Company is as set forth
in the Pricing Disclosure Package and the Prospectus in the column entitled
“Actual” under the caption “Capitalization” (except for subsequent issuances, if
any, pursuant to this Agreement, pursuant to reservations, agreements or
employee benefit plans referred to in the Pricing Disclosure Package and the
Prospectus or pursuant to the exercise of convertible securities or options
referred to in the Pricing Disclosure Package and the Prospectus. All
of the shares of the Company’s issued and outstanding capital stock have been
duly authorized and validly issued and are fully paid and non-assessable, and
none of the outstanding shares of capital stock were issued in violation of the
preemptive or other similar rights of any security holder of the
Company.
(q) This
Agreement has been duly authorized, executed and delivered by the
Company. The issue and sale of the Shares by the Company and the
performance by the Company of all of its obligations under this Agreement and
the consummation of the transactions contemplated herein and in the Prospectus
(including the use of the proceeds from the sale of the Shares as described in
the Pricing Disclosure Package and the Prospectus under the caption “Use of
Proceeds”) and compliance by the Company with its obligations hereunder have
been duly authorized by all necessary corporate action and do not and will not,
whether with or without the giving of notice or passage of time or both,
conflict with or constitute a breach of, or default or Repayment Event (as
defined below) under, (i) any indenture, mortgage, deed of trust, loan agreement
or other agreement or instrument to which the Company or any of its subsidiaries
is a party or by which the Company or any of its subsidiaries is bound or to
which any of the property or assets of the Company or any of its subsidiaries is
subject, (ii) the provisions of the articles of incorporation or regulations of
the Company or (iii) any statute or any order, rule or regulation of any
federal, state or local court or governmental agency (each a “Governmental Entity”) or body
having jurisdiction over the Company or any of its subsidiaries or any of their
properties except, with respect to clause (i), for those conflicts, breaches,
violations, defaults or Repayment Events that would not, individually or in the
aggregate, result in a Material Adverse Effect. No consent, approval,
authorization, order, registration or qualification of or with any such court or
governmental agency or body is required for the issue and sale of the Shares,
the performance by the Company of its obligations hereunder or the consummation
by the Company of the transactions contemplated by this Agreement, except (i)
the registration under the Securities Act of the Shares, (ii) as may be required
under the rules and regulations of the Nasdaq Global Select Market, (iii) such
consents, approvals, authorizations, registrations or qualifications as may be
required under state or foreign securities or Blue Sky laws in connection with
the purchase and distribution of the Shares by the Underwriters or (iv) where
the failure to obtain such consent, authorization, order or qualification would
not have a Material Adverse Effect. As used herein, a “Repayment Event” means any
event or condition which gives the holder of any note, debenture or other
evidence of indebtedness (or any person acting on such holder’s behalf) the
right to require the repurchase, redemption or repayment of all or a portion of
such indebtedness by the Company or any subsidiary.
6
(r) The
Shares to be purchased by the Underwriters from the Company have been duly
authorized for issuance and sale by the Company to the Underwriters pursuant to
this Agreement and, when issued and delivered by the Company pursuant to this
Agreement against payment of the consideration set forth herein, will be validly
issued and fully paid and non-assessable; the Common Shares conform in all
material respects to all statements relating thereto contained in the Pricing
Disclosure Package and the Prospectus and such description conforms in all
material respects to the rights set forth in the instruments defining the same;
no holder of the Shares will be subject to personal liability for the debts of
the Company by reason of being such a holder; and the issuance of the Shares is
not subject to the preemptive right, right of first refusal or other similar
rights of any security holder of the Company. Except as described in
the Pricing Disclosure Package and the Prospectus, (i) there are no
outstanding rights (contractual or statutory), warrants or options to acquire
from the Company, or instruments convertible into or exchangeable for, or
agreements or understandings with respect to the sale or issuance by the Company
of, any shares of capital stock of or other equity interest in the Company,
except as may have been granted by the Company pursuant to employee benefit
plans described in the Pricing Disclosure Package and the Prospectus in the
ordinary course of business and consistent with past practice, and
(ii) there are no contracts, agreements or understandings between the
Company and any person granting such person the right to require the Company to
file a registration statement under the Securities Act or otherwise register any
securities of the Company owned or to be owned by such person.
(s) Except
as described in the Pricing Disclosure Package and the Prospectus, neither the
Company nor any of its subsidiaries is in violation of its articles of
incorporation, regulations, or other similar constitutive documents, or in
default in the performance or observance of any obligation, agreement, covenant
or condition contained in any contract, indenture, mortgage, deed of trust, loan
or credit agreement, note, lease or other agreement or instrument to which the
Company or any of its subsidiaries is a party or by which it or any of them may
be bound (including, without limitation, any credit agreement, indenture, pledge
agreement, security agreement or other instrument or agreement evidencing,
guaranteeing, securing or relating to indebtedness of the Company or any of its
subsidiaries), or to which any of the property or assets of the Company or any
subsidiary is subject (collectively, “Agreements and Instruments”)
except for such defaults that would not, individually or in the aggregate,
result in a Material Adverse Effect.
7
(t) No
labor dispute with the employees of the Company or any subsidiary exists or, to
the knowledge of the Company, is imminent, which, in any case, may reasonably be
expected to result in a Material Adverse Effect.
(u) Except
as described in the most recent Preliminary Prospectus, there is no action,
suit, proceeding, inquiry or investigation before or brought by any court or
governmental agency or body, domestic or foreign, now pending, or, to the
knowledge of the Company, threatened, against or affecting the Company or any
subsidiary, which could reasonably be expected to result in a Material Adverse
Effect; the aggregate of all pending legal or governmental proceedings to which
the Company or any subsidiary is a party or of which any of their respective
property or assets is the subject which are not described in the Registration
Statement, Pricing Disclosure Package or Prospectus, including ordinary routine
litigation incidental to the business, could not reasonably be expected to
result in a Material Adverse Effect.
(v) Except
as disclosed in the Prospectus and the Pricing Disclosure Package, the Company
and its subsidiaries conduct their respective businesses in compliance in all
material respects with all federal, state, and local statutes, laws, rules,
regulations, decisions, directives and orders applicable to them, and neither
the Company nor any of its subsidiaries has received any written or, to the
Company’s knowledge, oral communication from any Governmental Entity asserting
that the Company or any of its subsidiaries is in material non-compliance with
any statute, law, rule, regulation, decision, directive or order.
(w) The
operations of the Company and its subsidiaries are currently in material
compliance with applicable financial record keeping and reporting requirements
of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the
money laundering statutes of all jurisdictions, the rules and regulations
thereunder and any related or similar rules, regulations or guidelines, issued,
administered or enforced by any governmental agency (collectively, the “Money Laundering Laws”) and
any instances of non-compliance have been resolved with the applicable
governmental agency and no formal action, suit or proceeding by or before any
court or governmental agency, authority or body or any arbitrator involving the
Company or any of its subsidiaries with respect to the Money Laundering Laws is
pending or, to the best knowledge of the Company, threatened. Neither
the Company nor any of its subsidiaries nor, to the knowledge of the Company,
any director, officer, agent, employee or affiliate of the Company or any of its
subsidiaries is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”); and the Company will
not directly or indirectly use the proceeds of the offering, or lend, contribute
or otherwise make available such proceeds to any subsidiary, joint venture
partner or other person or entity, for the purpose of financing the activities
of any person currently subject to any U.S. sanctions administered by
OFAC.
8
(x) The
Company and each of its subsidiaries own or possess adequate rights to use all
material patents, patent applications, trademarks, service marks, trade names,
trademark registrations, service xxxx registrations, copyrights, licenses,
know-how, software, systems and technology (including trade secrets and other
unpatented and/or unpatentable proprietary or confidential information, systems
or procedures) necessary for the conduct of their respective businesses and have
no reason to believe that the conduct of their respective businesses will
conflict with, and have not received any notice of any claim of conflict with,
any such rights of others.
(y) The
Company and its subsidiaries possess all material permits, licenses, approvals,
consents and other authorizations (collectively, “Governmental Licenses”) issued
by the appropriate federal, state or local regulatory agencies or bodies
necessary to conduct the business now operated by them; the Company and its
subsidiaries are in compliance with the terms and conditions of all such
Governmental Licenses, except where the failure to possess or so to comply would
not, individually or in the aggregate, have a Material Adverse Effect; all of
the Governmental Licenses are valid and in full force and effect, except where
the invalidity of such Governmental Licenses or the failure of such Governmental
Licenses to be in full force and effect would not, individually or in the
aggregate, have a Material Adverse Effect; and neither the Company nor any of
its subsidiaries has received any notice of proceedings relating to the
revocation or modification of any such Governmental Licenses which, individually
or in the aggregate, if the subject of an unfavorable decision, ruling or
finding, would result in a Material Adverse Effect. Neither the
Company nor any of its subsidiaries has failed to file with applicable
regulatory authorities any statement, report, information or form required by
any applicable law, regulation or order, except where the failure to so file
would not, individually or in the aggregate, have a Material Adverse Effect, all
such filings were in material compliance with applicable laws when filed and, to
the Company’s knowledge, no material deficiencies have been asserted by any
regulatory commission, agency or authority with respect to any such filings or
submissions.
(z) The
Company and its subsidiaries have good and marketable title to all real property
owned by the Company and its subsidiaries and good title to all personal
property owned by them, in each case, free and clear of all mortgages, pledges,
liens, security interests, claims, restrictions or encumbrances of any kind
except (i) such as are described in the Pricing Disclosure Package and the
Prospectus or (ii) where any encumbrances would not, individually or in the
aggregate, have a Material Adverse Effect; and all of the leases and subleases
material to the business of the Company and its subsidiaries, considered as one
enterprise, and under which the Company or any of its subsidiaries holds
properties described in the Pricing Disclosure Package and the Prospectus, are
in full force and effect, and neither the Company nor any subsidiary has any
written, or to the Company’s knowledge, oral notice of any material claim of any
sort that has been asserted by anyone adverse to the rights of the Company or
any subsidiary under any of the leases or subleases mentioned above, or
affecting or questioning the rights of the Company or such subsidiary to the
continued possession of the leased or subleased premises under any such lease or
sublease, except where the failure to be in effect or claim would not,
individually or in the aggregate, have a Material Adverse
Effect.
9
(aa) The
Company is not, and upon the issuance and sale of the Shares as herein
contemplated and the application of the net proceeds therefrom as described in
the Pricing Disclosure Package and the Prospectus will not be, an “investment
company” or an entity “controlled” by an “investment company” as such terms are
defined in the Investment Company Act of 1940, as amended.
(bb) Except
as described in the Pricing Disclosure Package and the Prospectus and except as
would not, individually or in the aggregate, result in a Material Adverse
Effect, (i) neither the Company nor any of its subsidiaries is in violation
in any material respect of any federal, state or local statute, law, rule,
regulation, ordinance, code, policy or rule of common law or any judicial or
administrative interpretation thereof, including any judicial or administrative
order, consent, decree or judgment, relating to pollution or protection of human
health, the environment (including, without limitation, ambient air, surface
water, groundwater, land surface or subsurface strata) or wildlife, including,
without limitation, laws and regulations relating to the release or threatened
release of chemicals, pollutants, contaminants, wastes, toxic substances,
hazardous substances, petroleum or petroleum products, asbestos-containing
materials or mold (collectively, “Hazardous Materials”) or to
the manufacture, processing, distribution, use, treatment, storage, disposal,
transport or handling of Hazardous Materials (collectively, “Environmental Laws”),
(ii) the Company and its subsidiaries have all material permits,
authorizations and approvals required under any applicable Environmental Laws
and are each in compliance with their requirements, and (iii) there are no
material pending or threatened administrative, regulatory or judicial actions,
suits, demands, demand letters, claims, liens, notices of noncompliance or
violation, investigation or proceedings relating to any Environmental Law
against the Company or any of its subsidiaries.
(cc) The
Company and each of its subsidiaries has (i) timely filed all necessary
foreign, United States federal, state and local tax returns, information
returns, and similar reports that are required to be filed (taking into account
valid extensions), and all tax returns are true, correct and complete and
(ii) paid in full all taxes required to be paid by it and any other fine or
penalty levied against it, except for any such tax assessment, fine or penalty
that is currently being contested in good faith or as would not, individually or
in the aggregate, reasonably be expected to have a Material Adverse
Effect. The Company has made adequate charges, accruals and reserves
in the applicable financial statements referred to in Section 1(l) above in
respect of all federal, state and foreign income and franchise taxes for all
periods as to which the tax liability of the Company or any of its consolidated
subsidiaries has not been finally determined.
(dd) Each
of the Company and its subsidiaries carry, or are covered by, insurance from
recognized, financially sound and reputable institutions with policies in such
amounts and with deductibles covering such risks as the Company reasonably
believes are adequate for the conduct of the business of the Company and its
subsidiaries and the value of their properties, including but not limited to,
policies covering real and personal property owned or leased by the Company and
its subsidiaries against theft, damage, destruction, acts of vandalism and
earthquakes; neither the Company nor any of its subsidiaries has been refused
any insurance coverage sought or applied for; and the Company is not aware that
they will not be able to renew their existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may
be necessary to continue its business at a cost that would not have a Material
Adverse Effect.
10
(ee) The
Company and each of its subsidiaries maintains a system of internal accounting
controls sufficient to provide reasonable assurance that (i) transactions
are executed in accordance with management’s general or specific authorizations;
(ii) transactions are recorded as necessary to permit preparation of
financial statements in conformity with generally accepted accounting principles
and to maintain asset accountability; (iii) access to assets is permitted
only in accordance with management’s general or specific authorization; and
(iv) the recorded accountability for assets is compared with the existing
assets at reasonable intervals and appropriate action is taken with respect to
any differences. Since the end of the Company’s most recent audited
fiscal year, there has been (x) no material weakness in the Company’s internal
control over financial reporting (whether or not remediated) and (y) no change
in the Company’s internal control over financial reporting that has materially
affected, or is reasonably likely to materially affect, the Company’s internal
control over financial reporting. The Company is not aware of any
significant deficiency in the design or operation of internal controls which
could adversely affect the Company’s ability to record, process, summarize and
report financial data or any material weaknesses in internal controls or any
fraud, whether or not material, that involves management or other employees who
have a significant role in the Company’s internal controls. Since the
most recent evaluation of the Company’s internal controls described above, there
have been no significant changes in internal controls or in other factors that
could significantly affect internal controls.
(ff) The
Company and its subsidiaries employ disclosure controls and procedures (as such
term is defined in Rule 13a-15 under the Exchange Act), which (i) are
designed to ensure that information required to be disclosed by the Company in
the reports that it files or submits under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified in the
Commission’s rules and forms and that material information relating to the
Company and its subsidiaries is made known to the Company’s principal executive
officer and principal financial officer by others within the Company and its
subsidiaries to allow timely decisions regarding disclosure, and (ii) are
effective in all material respects to perform the functions for which they were
established.
(gg) There
is and has been no failure on the part of the Company or any of the Company’s
directors or officers, in their capacities as such, to comply in all material
respects with any provision of the Xxxxxxxx-Xxxxx Act and the rules and
regulations promulgated in connection therewith, including Section 402 related
to loans and Sections 302 and 906 related to certifications.
(hh) The
Registration Statement is not the subject of a pending proceeding or examination
under Section 8(d) or 8(e) of the Securities Act, and the Company is not the
subject of a pending proceeding under Section 8A of the Securities Act in
connection with the offering of the Shares.
11
(ii) Neither
the Company nor any of its subsidiaries nor, to the knowledge of the Company,
any director, officer, agent, employee or other person associated with or acting
on behalf of the Company or any of its subsidiaries has (i) used any
corporate funds for any unlawful contribution, gift, entertainment or other
unlawful expense relating to political activity; (ii) made any direct or
indirect unlawful payment to any foreign or domestic government official or
employee from corporate funds; (iii) violated or is in violation of any
provision of the Foreign Corrupt Practices Act of 1977; or (iv) made any
bribe, rebate, payoff, influence payment, kickback or other unlawful payment,
except in the case of (i) and (ii) with respect to such contributions and
payments for which any applicable fines have been assessed against and paid by
the Company and that would not result, individually or in the aggregate, in a
Material Adverse Effect.
(jj) Except
as disclosed in the Pricing Disclosure Package and the Prospectus, no person has
the right to require the Company or any of its subsidiaries to register any
securities for sale under the Securities Act by reason of the filing of the
Registration Statement with the Commission or the issuance and sale of the
Shares to be sold by the Company hereunder.
(kk) Neither
the Company nor any of its subsidiaries, nor any affiliates of the Company or
its subsidiaries, has taken, directly or indirectly, any action designed to or
that could reasonably be expected to cause or result in any stabilization or
manipulation of the price of the Shares or any other “reference security” (as
defined in Rule 100 of Regulation M under the Exchange Act (“Regulation M”)) whether to
facilitate the sale or resale of the Shares or otherwise, and has taken no
action which would directly or indirectly violate Regulation M. The
Company acknowledges that the Underwriters may engage in passive market making
transactions in the Common Shares on the Nasdaq Global Select Market in
accordance with Regulation M.
(ll) The
Company has not distributed and, prior to the later to occur of (i) the Initial
Delivery Date and (ii) completion of the distribution of the Shares, will not
distribute any prospectus (as such term is defined in the Securities Act and the
Rules and Regulations) in connection with the offering and sale of the Shares
other than the Registration Statement, any Preliminary Prospectus, the
Prospectus or other materials, if any, permitted by the Securities Act or by the
Rules and Regulations and approved prior to such use by the
Underwriters.
(mm) Each
of the Company’s executive officers and directors, in each case as listed on
Schedule 2
hereto, has executed and delivered to the Representative lock-up agreements as
contemplated by Section 5(a)(x) hereof. If any additional
persons shall become directors or officers of the Company prior to the end of
the Lock-up Period (as defined below), the Company shall cause such person,
prior to or contemporaneously with their appointment or election as a director
or officer of the Company, to execute and deliver to the Representative an
agreement in the form attached hereto as Exhibit A.
12
(nn) The
Company and each of the subsidiaries or their “ERISA Affiliates” (as defined
below) are in compliance in all material respects with all presently applicable
provisions of the Employee Retirement Income Security Act of 1974, as amended,
including the regulations and published interpretations thereunder (“ERISA”); no “reportable event”
(as defined in ERISA) has occurred with respect to any “employee benefit plan”
(as defined in ERISA) for which the Company or any of the subsidiaries or ERISA
Affiliates would have any liability; the Company and each of the subsidiaries or
their ERISA Affiliates have not incurred and do not expect to incur (i) any
liability under Title IV of ERISA with respect to termination of, or withdrawal
from, any “employee benefit plan” or (ii) any material liability under Sections
412, 4971, 4975 or 4980B of the United States Internal Revenue Code of 1986, as
amended, and the regulations and published interpretations thereunder
(collectively the “Code”); and each “employee
benefit plan” for which the Company and each of its subsidiaries or any of their
ERISA Affiliates would have any liability that is intended to be qualified under
Section 401(a) of the Code has received a favorable determination or approval
letter from the Internal Revenue Service regarding its qualification under such
section and nothing has occurred, whether by action or by failure to act, which
would reasonably be expected to cause the loss of such
qualification. “ERISA Affiliate” means, with
respect to the Company or a subsidiary, any member of any group of organizations
described in Sections 414(b), (c), (m) or (o) of the Code or Section 4001(b) of
ERISA of which the Company or such subsidiary is a member.
(oo) Except
as disclosed in the Pricing Disclosure Package and the Prospectus, no subsidiary
of the Company is prohibited or restricted, directly or indirectly, from paying
dividends to the Company, or from making any other distribution with respect to
such subsidiary’s equity securities or from repaying to the Company or any other
subsidiary of the Company any amounts that may from time to time become due
under any loans or advances to such subsidiary from the Company or from
transferring any property or assets to the Company or to any other
subsidiary.
Any
certificate signed by any officer of the Company and delivered to the
Representative or counsel for the Underwriters in connection with the offering
of the Shares shall be deemed a representation and warranty by the Company, as
to matters covered thereby, to each Underwriter.
2.
Purchase of the Shares by the
Underwriters. On the basis of the representations and
warranties contained in, and subject to the terms and conditions of, this
Agreement, the Company agrees to sell 5,614,200 Firm Shares to the several
Underwriters, and each of the Underwriters, severally and not jointly, agrees to
purchase the number of Firm Shares set forth opposite that Underwriter’s name in
Schedule 1
hereto. The respective purchase obligations of the Underwriters with
respect to the Firm Shares shall be rounded among the Underwriters to avoid
fractional shares, as the Representative may determine.
In
addition, the Company grants to the Underwriters an option to purchase up to
757,917 additional Option Shares. Such option is exercisable in the event that
the Underwriters sell more Shares than the number of Firm Shares in the offering
and as set forth in Section 4 hereof. Each Underwriter agrees,
severally and not jointly, to purchase the number of Option Shares (subject to
such adjustments to eliminate fractional shares as the Representative may
determine) that bears the same proportion to the total number of shares of
Option Shares to be sold on such Delivery Date as the number of shares of Firm
Shares set forth in Schedule 1 hereto
opposite the name of such Underwriter bears to the total number of Firm
Shares.
13
The price
of both the Firm Shares and any Option Shares purchased by the Underwriters
shall be $14.3830 per share.
The
Company shall not be obligated to deliver any of the Firm Shares or Option
Shares to be delivered on the applicable Delivery Date, except upon payment for
all such Shares to be purchased on such Delivery Date as provided
herein.
3.
Offering of Shares by the
Underwriters. Upon authorization by the Representative of the
release of the Firm Shares, the several Underwriters propose to offer the Firm
Shares for sale upon the terms and conditions to be set forth in the
Prospectus.
4.
Delivery of and Payment for
the Shares. Delivery of and payment for the Firm Shares shall
be made at 10:00 A.M., New York City time, on the third business day
following the date of this Agreement or at such other date or place as shall be
determined by agreement between the Representative and the
Company. This date and time are sometimes referred to as the “Initial Delivery
Date.” Delivery of the Firm Shares shall be made to the
Representative for the account of each Underwriter against payment by the
several Underwriters through the Representative and of the respective aggregate
purchase prices of the Firm Shares being sold by the Company to or upon the
order of the Company of the purchase price by wire transfer in immediately
available funds to the accounts specified by the Company. Time shall
be of the essence, and delivery at the time and place specified pursuant to this
Agreement is a further condition of the obligation of each Underwriter
hereunder. The Company shall deliver the Firm Shares through the
facilities of DTC unless the Representative shall otherwise
instruct.
The
option granted in Section 2 will expire 30 days after the date of this Agreement
and may be exercised in whole or from time to time in part by written notice
being given to the Company by the Representative; provided, that if such date
falls on a day that is not a business day, the option granted in Section 2 will
expire on the next succeeding business day. Such notice shall set
forth the aggregate number of Option Shares as to which the option is being
exercised, the names in which the Option Shares are to be registered, the
denominations in which the Option Shares are to be issued and the date and time,
as determined by the Representative, when the Option Shares are to be delivered;
provided, however, that this date and
time shall not be earlier than the Initial Delivery Date nor earlier than the
second business day after the date on which the option shall have been exercised
nor later than the fifth business day after the date on which the option shall
have been exercised. Each date and time the Option Shares are
delivered is sometimes referred to as an “Option Shares Delivery Date,”
and the Initial Delivery Date and any Option Shares Delivery Date are sometimes
each referred to as a “Delivery
Date.”
14
Delivery
of the Option Shares by the Company and payment for the Option Shares by the
several Underwriters through the Representative shall be made at
10:00 A.M., New York City time, on the date specified in the corresponding
notice described in the preceding paragraph or at such other date or place as
shall be determined by agreement between the Representative and the
Company. On the Option Shares Delivery Date, the Company shall
deliver or cause to be delivered the Option Shares to the Representative for the
account of each Underwriter against payment by the several Underwriters through
the Representative and of the respective aggregate purchase prices of the Option
Shares being sold by the Company to or upon the order of the Company of the
purchase price by wire transfer in immediately available funds to the accounts
specified by the Company. Time shall be of the essence, and delivery
at the time and place specified pursuant to this Agreement is a further
condition of the obligation of each Underwriter hereunder. The
Company shall deliver the Option Shares through the facilities of DTC unless the
Representative shall otherwise instruct.
5.
Further Agreements of the
Company and the Underwriters. (a) The Company
agrees:
(i)
To prepare the Prospectus in a form approved by the
Representative and to file such Prospectus pursuant to Rule 424(b) under the
Securities Act not later than the Commission’s close of business on the second
business day following the execution and delivery of this Agreement; to make no
further amendment or any supplement to the Registration Statement or the
Prospectus prior to the last Delivery Date except as provided herein; to advise
the Representative, promptly after it receives notice thereof, of the time when
any amendment or supplement to the Registration Statement or the Prospectus has
been filed and to furnish the Representative with copies thereof; to file
promptly all reports and any definitive proxy or information statements required
to be filed by the Company with the Commission pursuant to Section 13(a), 13(c),
14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for
so long as the delivery of a prospectus is required in connection with the
offering or sale of the Shares; to advise the Representative, promptly after it
receives notice thereof, of the issuance by the Commission of any stop order or
of any order preventing or suspending the use of the Prospectus or any Issuer
Free Writing Prospectus, of the suspension of the qualification of the Shares
for offering or sale in any jurisdiction, of the initiation or threatening of
any proceeding or examination for any such purpose or of any request by the
Commission for the amending or supplementing of the Registration Statement, the
Prospectus or any Issuer Free Writing Prospectus or for additional information;
and, in the event of the issuance of any stop order or of any order preventing
or suspending the use of the Prospectus or any Issuer Free Writing Prospectus or
suspending any such qualification, to use promptly its best efforts to obtain
its withdrawal;
(ii) To
furnish promptly to the Representative and to counsel for the Underwriters a
signed copy of the Registration Statement as originally filed with the
Commission, and each amendment thereto filed with the Commission, including all
consents and exhibits filed therewith;
15
(iii) To
deliver promptly to the Representative such number of the following documents as
the Representative shall reasonably request: (A) conformed copies of
the Registration Statement as originally filed with the Commission and each
amendment thereto (in each case excluding exhibits other than this Agreement and
the computation of per share earnings), (B) each Preliminary Prospectus, the
Prospectus and any amended or supplemented Prospectus, (C) each Issuer Free
Writing Prospectus and (D) any document incorporated by reference in any
Preliminary Prospectus or the Prospectus; and, if the delivery of a prospectus
is required at any time after the date hereof in connection with the offering or
sale of the Shares or any other securities relating thereto and if at such time
any events shall have occurred as a result of which the Prospectus as then
amended or supplemented would include an untrue statement of a material fact or
omit to state any material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made when such
Prospectus is delivered, not misleading, or, if for any other reason it shall be
necessary to amend or supplement the Prospectus or to file under the Exchange
Act any document incorporated by reference in the Prospectus in order to comply
with the Securities Act or the Exchange Act, to notify the Representative and,
upon its request, to file such document and to prepare and furnish without
charge to each Underwriter and to any dealer in securities as many copies as the
Representative may from time to time reasonably request of an amended or
supplemented Prospectus that will correct such statement or omission or effect
such compliance;
(iv) To
file promptly with the Commission any amendment or supplement to the
Registration Statement or the Prospectus that may, in the judgment of the
Company or the Representative, be required by the Securities Act or requested by
the Commission;
(v) Prior
to filing with the Commission any amendment or supplement to the Registration
Statement or the Prospectus, any document incorporated by reference in the
Prospectus or any amendment to any document incorporated by reference in the
Prospectus, to furnish a copy thereof to the Representative and counsel for the
Underwriters and obtain the consent of the Representative to the
filing;
(vi) Not
to make any offer relating to the Shares that would constitute an Issuer Free
Writing Prospectus without the prior written consent of the
Representative;
(vii) To
comply with all applicable requirements of Rule 433 with respect to any Issuer
Free Writing Prospectus; and if at any time after the date hereof any events
shall have occurred as a result of which any Issuer Free Writing Prospectus, as
then amended or supplemented, would conflict with the information in the
Registration Statement, the most recent Preliminary Prospectus or the Prospectus
or would include an untrue statement of a material fact or omit to state any
material fact necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading, or, if for any
other reason it shall be necessary to amend or supplement any Issuer Free
Writing Prospectus, to notify the Representative and, upon its request, to file
such document and to prepare and furnish without charge to each Underwriter as
many copies as the Representative may from time to time reasonably request of an
amended or supplemented Issuer Free Writing Prospectus that will correct such
conflict, statement or omission or effect such compliance;
(viii) As
soon as practicable after the Effective Date and in any event not later than 16
months after the date hereof, to make generally available to the Company’s
security holders and to deliver to the Representative an earnings statement of
the Company and its subsidiaries (which need not be audited) complying with
Section 11(a) of the Securities Act and the Rules and Regulations; provided that the Company may
make such earnings statements generally available by filing quarterly and annual
reports with the Commission as may be required by the Exchange
Act;
16
(ix) Promptly
from time to time to take such action as the Representative may reasonably
request to qualify the Shares for offering and sale under the securities laws of
Canada and such other jurisdictions as the Representative may reasonably request
and to comply with such laws so as to permit the continuance of sales and
dealings therein in such jurisdictions for as long as may be necessary to
complete the distribution of the Shares; provided, that in connection
therewith the Company shall not be required to (i) qualify as a foreign
corporation in any jurisdiction in which it would not otherwise be required to
so qualify, (ii) file a general consent to service of process in any such
jurisdiction or (iii) subject itself to taxation in any jurisdiction in which it
would not otherwise be subject;
(x) For
a period commencing on the date hereof and ending on the 90th day after the date
of the Prospectus (the “Lock-Up
Period”), not to, directly or indirectly, (1) offer for sale, sell,
pledge or otherwise dispose of (or enter into any transaction or device that is
designed to, or could be expected to, result in the disposition by any person at
any time in the future of) any Common Shares or securities convertible into or
exchangeable for Common Shares (other than the Shares and Common Shares issued
pursuant to employee benefit plans, qualified stock option plans or other
employee compensation plans existing on the date hereof or pursuant to currently
outstanding options, warrants or rights not issued under one of those plans or
pursuant to the Company’s existing dividend reinvestment program), or sell or
grant options, rights or warrants with respect to any Common Shares or
securities convertible into or exchangeable for Common Shares (other than the
grant of options pursuant to option plans existing on the date hereof), (2)
enter into any swap or other derivatives transaction that transfers to another,
in whole or in part, any of the economic benefits or risks of ownership of such
Common Shares, whether any such transaction described in clause (1) or (2) above
is to be settled by delivery of Common Shares or other securities, in cash or
otherwise, (3) file or cause to be filed a registration statement, including any
amendments, with respect to the registration of any Common Shares or securities
convertible, exercisable or exchangeable into Common Shares or any other
securities of the Company, except for any registration statements on Form S-8
(as promulgated under the Securities Act) or its then equivalent relating to
equity securities issuable in connection with stock option or other employee
benefit plans or (4) publicly disclose the intention to do any of the foregoing,
in each case without the prior written consent of Barclays Capital Inc., on
behalf of the Underwriters, and to cause each officer and director of the
Company set forth on Schedule 2 hereto to
furnish to the Representative, prior to the Initial Delivery Date, a letter or
letters, substantially in the form of Exhibit A hereto (the
“Lock-Up Agreements”);
notwithstanding the foregoing, if (1) during the last 17 days of the Lock-Up
Period, the Company issues an earnings release or material news or a material
event relating to the Company occurs or (2) prior to the expiration of the
Lock-Up Period, the Company announces that it will release earnings results
during the 16-day period beginning on the last day of the Lock-Up Period, then
the restrictions imposed in this paragraph shall continue to apply until the
expiration of the 18-day period beginning on the issuance of the earnings
release or the announcement of the material news or the occurrence of the
material event, unless the Representative waives such extension in
writing;
17
(xi) To
apply the net proceeds from the sale of the Shares being sold by the Company as
set forth in the Prospectus; and
(xii) To
use its best efforts to cause the Shares to be approved for inclusion, subject
to official notice of issuance, in The NASDAQ Global Select Market.
(b) Each
Underwriter severally agrees that such Underwriter shall not include any “issuer
information” (as defined in Rule 433) in any “free writing prospectus” (as
defined in Rule 405) used or referred to by such Underwriter without the prior
consent of the Company (any such issuer information with respect to whose use
the Company has given its consent, “Permitted Issuer
Information”); provided, that (i) no such
consent shall be required with respect to any such issuer information contained
in any document filed by the Company with the Commission prior to the use of
such free writing prospectus and (ii) “issuer information,” as used in this
Section 5(b), shall not be deemed to include information prepared by or on
behalf of such Underwriter on the basis of or derived from issuer
information.
6.
Expenses. The
Company agrees, whether or not the transactions contemplated by this Agreement
are consummated or this Agreement is terminated, to pay all costs, expenses,
fees and taxes incident to and in connection with (a) the authorization,
issuance, sale and delivery of the Shares and any stamp duties or other taxes
payable in that connection, and the preparation and printing of certificates for
the Shares; (b) the preparation, printing and filing under the Securities Act of
the Registration Statement (including any exhibits thereto), any Preliminary
Prospectus, the Prospectus, any Issuer Free Writing Prospectus and any amendment
or supplement thereto; (c) the distribution of the Registration Statement
(including any exhibits thereto), any Preliminary Prospectus, the Prospectus,
any Issuer Free Writing Prospectus and any amendment or supplement thereto, or
any document incorporated by reference therein, all as provided in this
Agreement; (d) the production and distribution of this Agreement, any
supplemental agreement among Underwriters, and any other related documents in
connection with the offering, purchase, sale and delivery of the Shares; (e) any
required review by the FINRA of the terms of sale of the Shares (including
related fees and expenses of counsel to the Underwriters in an amount that is
not greater than $3,500); (f) the inclusion of the Shares on The
NASDAQ Global Select Market and/or any other exchange; (g) the qualification of
the Shares under the securities laws of the several jurisdictions as provided in
Section 5(a)(ix) and the preparation, printing and distribution of a Blue Sky
Memorandum (including related fees and expenses of counsel to the Underwriters);
(h) the preparation, printing and distribution of one or more versions of the
Preliminary Prospectus and the Prospectus for distribution in Canada, often in
the form of a Canadian “wrapper” (including related fees and expenses of
Canadian counsel to the Underwriters); (i) the investor presentations on any
“road show” undertaken in connection with the marketing of the Shares,
including, without limitation, expenses associated with any electronic roadshow,
travel and lodging expenses of the representatives and officers of the Company
and the cost of any aircraft chartered in connection with the road show; and (j)
all other costs and expenses incident to the performance of the obligations of
the Company under this Agreement; provided, that, except as
provided in this Section 6 and in Section 11, the Underwriters shall pay their
own costs and expenses, including the costs and expenses of their counsel, any
transfer taxes on the Shares which they may sell and the expenses of advertising
any offering of the Shares made by the Underwriters.
18
7.
Conditions of Underwriters’
Obligations. The respective obligations of the Underwriters
hereunder are subject to the accuracy, when made and on each Delivery Date, of
the representations and warranties of the Company contained herein, to the
performance by the Company of its obligations hereunder, and to each of the
following additional terms and conditions:
(a) The
Prospectus shall have been timely filed with the Commission in accordance with
Section 5(a)(i); the Company shall have complied with all filing requirements
applicable to any Issuer Free Writing Prospectus used or referred to after the
date hereof; no stop order suspending the effectiveness of the Registration
Statement or preventing or suspending the use of the Prospectus or any Issuer
Free Writing Prospectus shall have been issued and no proceeding or examination
for such purpose shall have been initiated or threatened by the Commission; and
any request of the Commission for inclusion of additional information in the
Registration Statement or the Prospectus or otherwise shall have been complied
with.
(b) No
Underwriter shall have discovered and disclosed to the Company on or prior to
such Delivery Date that the Registration Statement, the Prospectus or the
Pricing Disclosure Package, or any amendment or supplement thereto, contains an
untrue statement of a fact which is material or omits to state a fact which, in
the opinion of such counsel, is material and is required to be stated therein or
is necessary to make the statements therein not misleading.
(c) All
corporate proceedings and other legal matters incident to the authorization,
form and validity of this Agreement, the Shares, the Registration Statement, the
Prospectus and any Issuer Free Writing Prospectus, and all other legal matters
relating to this Agreement and the transactions contemplated hereby shall be
reasonably satisfactory in all material respects to counsel for the
Underwriters, and the Company shall have furnished to such counsel all documents
and information that they may reasonably request to enable them to pass upon
such matters.
(d) Squire,
Xxxxxxx & Xxxxxxx L.L.P. shall have furnished to the Representative its
written opinion, as counsel to the Company, addressed to the Underwriters and
dated such Delivery Date, in form and substance reasonably satisfactory to the
Representative, substantially in the form attached hereto as Exhibit
B-1.
(e) Xxxxxxx
X. Xxxxxxxx, Senior Vice President and General Counsel of the Company, shall
have furnished to the Representative his written opinion addressed to the
Underwriters and dated such Delivery Date, in form and substance reasonably
satisfactory to the Representative, substantially in the form attached hereto as
Exhibit
B-2.
19
(f) The
Representative shall have received from Xxxxxxxx & Xxxxxxxx LLP, counsel for
the Underwriters, such opinion or opinions, dated such Delivery Date, with
respect to the issuance and sale of the Shares, the Registration Statement, the
Prospectus and the Pricing Disclosure Package and other related matters as the
Representative may reasonably require, and the Company shall have furnished to
such counsel such documents as they may reasonably request for the purpose of
enabling them to pass upon such matters. Xxxxxxxx & Xxxxxxxx LLP
may rely as to matters involving laws of the State of Ohio upon the opinions of
Squire, Xxxxxxx & Xxxxxxx L.L.P. and Xxxxxxx X. Xxxxxxxx delivered pursuant
to Sections 7(d) and (e), respectively.
(g) At
the time of execution of this Agreement, the Representative shall have received
from Ernst & Young LLP a letter, in form and substance satisfactory to the
Representative, addressed to the Underwriters and dated the date hereof (i)
confirming that they are an independent registered public accounting firm within
the meaning of the Securities Act and are in compliance with the applicable
requirements relating to the qualification of accountants under Rule 2-01
of Regulation S-X of the Commission, and (ii) stating, as of the date hereof
(or, with respect to matters involving changes or developments since the
respective dates as of which specified financial information is given in the
most recent Preliminary Prospectus, as of a date not more than three days prior
to the date hereof), the conclusions and findings of such firm with respect to
the financial information and other matters ordinarily covered by accountants’
“comfort letters” to underwriters in connection with registered public
offerings, including with respect to the Company’s earnings report for the three
months and twelve months ended December 31, 2009 incorporated in the Pricing
Disclosure Package.
(h) With
respect to the letter of Ernst & Young LLP referred to in the preceding
paragraph and delivered to the Representative concurrently with the execution of
this Agreement (the “initial
letter”), the Company shall have furnished to the Representative a letter
(the “bring-down
letter”) of such accountants, addressed to the Underwriters and dated
such Delivery Date (i) confirming that they are an independent registered
public accounting firm within the meaning of the Securities Act and are in
compliance with the applicable requirements relating to the qualification of
accountants under Rule 2-01 of Regulation S-X of the Commission,
(ii) stating, as of the date of the bring-down letter (or, with respect to
matters involving changes or developments since the respective dates as of which
specified financial information is given in the Prospectus, as of a date not
more than three days prior to the date of the bring-down letter), the
conclusions and findings of such firm with respect to the financial information
and other matters covered by the initial letter and (iii) confirming in all
material respects the conclusions and findings set forth in the initial
letter.
(i) The
Company shall have furnished to the Representative a certificate, dated such
Delivery Date, of its Chief Executive Officer and its Chief Financial Officer
stating that:
(i) The
representations, warranties and agreements of the Company in Section 1 are
true and correct on and as of such Delivery Date, and the Company has complied
with all its agreements contained herein and satisfied all the conditions on its
part to be performed or satisfied hereunder at or prior to such Delivery Date;
and
20
(ii) No
stop order suspending the effectiveness of the Registration Statement has been
issued; and no proceedings or examination for that purpose have been instituted
or, to the knowledge of such officers, threatened.
(j)
The Company shall have furnished to the
Representative a certificate, dated such Delivery Date, of its Chief Financial
Officer substantially in the form attached hereto as Exhibit
C.
(k) Except
as described in the most recent Preliminary Prospectus, (i) neither the Company
nor any of its subsidiaries shall have sustained, since the date of the latest
audited financial statements included or incorporated by reference in the most
recent Preliminary Prospectus, any loss or interference with its business from
fire, explosion, flood or other calamity, whether or not covered by insurance,
or from any labor dispute or court or governmental action, order or decree or
(ii) since such date there shall not have been any change in the capital stock
or long-term debt of the Company or any of its subsidiaries or any change, or
any development involving a prospective change, in or affecting the condition
(financial or otherwise), results of operations, shareholders’ equity,
properties, management, business or prospects of the Company and its
subsidiaries taken as a whole, the effect of which, in any such case described
in clause (i) or (ii), is, in the judgment of the Representative, so material
and adverse as to make it impracticable or inadvisable to proceed with the
public offering or the delivery of the Shares being delivered on such Delivery
Date on the terms and in the manner contemplated in the Prospectus.
(l)
Subsequent to the execution and delivery of this
Agreement there shall not have occurred any of the following: (i)
trading in securities generally on the New York Stock Exchange or the American
Stock Exchange or in the over-the-counter market, or trading in any securities
of the Company on any exchange or in the over-the-counter market, shall have
been suspended or materially limited or the settlement of such trading generally
shall have been materially disrupted or minimum prices shall have been
established on any such exchange or such market by the Commission, by such
exchange or by any other regulatory body or governmental authority having
jurisdiction, (ii) a banking moratorium shall have been declared by federal or
state authorities, (iii) the United States shall have become engaged in
hostilities, there shall have been an escalation in hostilities involving the
United States or there shall have been a declaration of a national emergency or
war by the United States or (iv) there shall have occurred such a material
adverse change in general economic, political or financial conditions,
including, without limitation, as a result of terrorist activities after the
date hereof (or the effect of international conditions on the financial markets
in the United States shall be such), as to make it, in the judgment of the
Representative, impracticable or inadvisable to proceed with the public offering
or delivery of the Shares being delivered on such Delivery Date on the terms and
in the manner contemplated in the Prospectus.
(m) The
NASDAQ Global Select Market shall have approved the Shares for inclusion,
subject only to official notice of issuance.
21
(n) The
Lock-Up Agreements between the Representative and the officers and directors of
the Company set forth on Schedule 2, delivered
to the Representative on or before the date of this Agreement, shall be in full
force and effect on such Delivery Date.
All
opinions, letters, evidence and certificates mentioned above or elsewhere in
this Agreement shall be deemed to be in compliance with the provisions hereof
only if they are in form and substance reasonably satisfactory to
counsel for the Underwriters.
8.
Indemnification and
Contribution.
(a) The
Company shall indemnify and hold harmless each Underwriter, its directors,
officers and employees and each person, if any, who controls any Underwriter
within the meaning of Section 15 of the Securities Act, from and against any
loss, claim, damage or liability, joint or several, or any action in respect
thereof (including, but not limited to, any loss, claim, damage, liability or
action relating to purchases and sales of Shares), to which that Underwriter,
director, officer, employee or controlling person may become subject, under the
Securities Act or otherwise, insofar as such loss, claim, damage, liability or
action arises out of, or is based upon, (i) any untrue statement or alleged
untrue statement of a material fact contained in (A) any Preliminary Prospectus,
the Registration Statement, the Prospectus or in any amendment or supplement
thereto, (B) any Issuer Free Writing Prospectus or in any amendment or
supplement thereto or (C) any Permitted Issuer Information used or referred to
in any “free writing prospectus” (as defined in Rule 405) used or referred to by
any Underwriter, (D) any “road show” (as defined in Rule 433) not constituting
an Issuer Free Writing Prospectus (a “Non-Prospectus Road Show”) or
(E) any Blue Sky application or other document prepared or executed by the
Company (or based upon any written information furnished by the Company for use
therein) specifically for the purpose of qualifying any or all of the Shares
under the securities laws of any state or other jurisdiction (any such
application, document or information being hereinafter called a “Blue Sky Application”) or (ii)
the omission or alleged omission to state in any Preliminary Prospectus, the
Registration Statement, the Prospectus, any Issuer Free Writing Prospectus or in
any amendment or supplement thereto or in any Permitted Issuer Information, any
Non-Prospectus Road Show or any Blue Sky Application, any material fact required
to be stated therein or necessary to make the statements therein not misleading,
and shall reimburse each Underwriter and each such director, officer, employee
or controlling person promptly upon demand for any legal or other expenses
reasonably incurred by that Underwriter, director, officer, employee or
controlling person in connection with investigating or defending or preparing to
defend against any such loss, claim, damage, liability or action as such
expenses are incurred; provided, however, that the Company
shall not be liable in any such case to the extent that any such loss, claim,
damage, liability or action arises out of, or is based upon, any untrue
statement or alleged untrue statement or omission or alleged omission made in
any Preliminary Prospectus, the Registration Statement, the Prospectus, any
Issuer Free Writing Prospectus or in any such amendment or supplement thereto or
in any Permitted Issuer Information, any Non-Prospectus Road Show or any Blue
Sky Application, in reliance upon and in conformity with written information
concerning such Underwriter furnished to the Company through the Representative
by or on behalf of any Underwriter specifically for inclusion therein, which
information consists solely of the information specified in Section
8(e). The foregoing indemnity agreement is in addition to any
liability which the Company may otherwise have to any Underwriter or to any
director, officer, employee or controlling person of that
Underwriter.
22
(b) Each
Underwriter, severally and not jointly, shall indemnify and hold harmless the
Company, its directors, officers and employees, and each person, if any, who
controls the Company within the meaning of Section 15 of the Securities Act,
from and against any loss, claim, damage or liability, joint or several, or any
action in respect thereof, to which the Company or any such director, officer,
employee or controlling person may become subject, under the Securities Act or
otherwise, insofar as such loss, claim, damage, liability or action arises out
of, or is based upon, (i) any untrue statement or alleged untrue statement of a
material fact contained in any Preliminary Prospectus, the Registration
Statement, the Prospectus, any Issuer Free Writing Prospectus or in any
amendment or supplement thereto or in any Non-Prospectus Road Show or Blue Sky
Application, or (ii) the omission or alleged omission to state in any
Preliminary Prospectus, the Registration Statement, the Prospectus, any Issuer
Free Writing Prospectus or in any amendment or supplement thereto or in any
Non-Prospectus Road Show or Blue Sky Application, any material fact required to
be stated therein or necessary to make the statements therein not misleading,
but in each case only to the extent that the untrue statement or alleged untrue
statement or omission or alleged omission was made in reliance upon and in
conformity with written information concerning such Underwriter furnished to the
Company through the Representative by or on behalf of that Underwriter
specifically for inclusion therein, which information is limited to the
information set forth in Section 8(e). The foregoing indemnity
agreement is in addition to any liability that any Underwriter may otherwise
have to the Company or any such director, officer, employee or controlling
person.
23
(c) Promptly
after receipt by an indemnified party under this Section 8 of notice of any
claim or the commencement of any action, the indemnified party shall, if a claim
in respect thereof is to be made against the indemnifying party under this
Section 8, notify the indemnifying party in writing of the claim or the
commencement of that action; provided, however, that the failure to
notify the indemnifying party shall not relieve it from any liability which it
may have under this Section 8 except to the extent it has been materially
prejudiced by such failure and, provided, further, that the failure to
notify the indemnifying party shall not relieve it from any liability which it
may have to an indemnified party otherwise than under this Section
8. If any such claim or action shall be brought against an
indemnified party, and it shall notify the indemnifying party thereof, the
indemnifying party shall be entitled to participate therein and, to the extent
that it wishes, jointly with any other similarly notified indemnifying party, to
assume the defense thereof with counsel reasonably satisfactory to the
indemnified party. After notice from the indemnifying party to the
indemnified party of its election to assume the defense of such claim or action,
the indemnifying party shall not be liable to the indemnified party under this
Section 8 for any legal or other expenses subsequently incurred by the
indemnified party in connection with the defense thereof other than reasonable
costs of investigation; provided, however, that the indemnified
party shall have the right to employ counsel to represent jointly the
indemnified party and those other indemnified parties and their respective
directors, officers, employees and controlling persons who may be subject to
liability arising out of any claim in respect of which indemnity may be sought
under this Section 8 if (i) the indemnified party and the indemnifying party
shall have so mutually agreed; (ii) the indemnifying party has failed within a
reasonable time to retain counsel reasonably satisfactory to the indemnified
party; (iii) the indemnified party and its directors, officers, employees and
controlling persons shall have reasonably concluded that there may be legal
defenses available to them that are different from or in addition to those
available to the indemnifying party; or (iv) the named parties in any such
proceeding (including any impleaded parties) include both the indemnified
parties or their respective directors, officers, employees or controlling
persons, on the one hand, and the indemnifying party, on the other hand, and
representation of both sets of parties by the same counsel would be
inappropriate due to actual or potential differing interests between them, and
in any such event the fees and expenses of such separate counsel shall be paid
by the indemnifying party. No indemnifying party shall
(i) without the prior written consent of the indemnified parties (which
consent shall not be unreasonably withheld), settle or compromise or consent to
the entry of any judgment with respect to any pending or threatened claim,
action, suit or proceeding in respect of which indemnification or contribution
may be sought hereunder (whether or not the indemnified parties are actual or
potential parties to such claim or action) unless such settlement, compromise or
consent includes an unconditional release of each indemnified party from all
liability arising out of such claim, action, suit or proceeding and does not
include any findings of fact or admissions of fault or culpability as to the
indemnified party, or (ii) be liable for any settlement of any such action
effected without its written consent (which consent shall not be unreasonably
withheld), but if settled with the consent of the indemnifying party or if there
be a final judgment for the plaintiff in any such action, the indemnifying party
agrees to indemnify and hold harmless any indemnified party from and against any
loss or liability by reason of such settlement or judgment.
24
(d) If
the indemnification provided for in this Section 8 shall for any reason be
unavailable to or insufficient to hold harmless an indemnified party under
Section 8(a) or 8(b) in respect of any loss, claim, damage or liability, or any
action in respect thereof, referred to therein, then each indemnifying party
shall, in lieu of indemnifying such indemnified party, contribute to the amount
paid or payable by such indemnified party as a result of such loss, claim,
damage or liability, or action in respect thereof, (i) in such proportion as
shall be appropriate to reflect the relative benefits received by the Company,
on the one hand, and the Underwriters, on the other, from the offering of the
Shares or (ii) if the allocation provided by clause (i) above is not permitted
by applicable law, in such proportion as is appropriate to reflect not only the
relative benefits referred to in clause (i) above but also the relative fault of
the Company, on the one hand, and the Underwriters, on the other, with respect
to the statements or omissions that resulted in such loss, claim, damage or
liability, or action in respect thereof, as well as any other relevant equitable
considerations. The relative benefits received by the Company, on the
one hand, and the Underwriters, on the other, with respect to such offering
shall be deemed to be in the same proportion as the total net proceeds from the
offering of the Shares purchased under this Agreement (before deducting
expenses) received by the Company, as set forth in the table on the cover page
of the Prospectus, on the one hand, and the total underwriting discounts and
commissions received by the Underwriters with respect to the Shares purchased
under this Agreement, as set forth in the table on the cover page of the
Prospectus, on the other hand. The relative fault shall be determined
by reference to whether the untrue or alleged untrue statement of a material
fact or omission or alleged omission to state a material fact relates to
information supplied by the Company or the Underwriters, the intent of the
parties and their relative knowledge, access to information and opportunity to
correct or prevent such statement or omission. The Company and the
Underwriters agree that it would not be just and equitable if contributions
pursuant to this Section 8(d) were to be determined by pro rata allocation (even
if the Underwriters were treated as one entity for such purpose) or by any other
method of allocation that does not take into account the equitable
considerations referred to herein. The amount paid or payable by an
indemnified party as a result of the loss, claim, damage or liability, or action
in respect thereof, referred to above in this Section 8(d) shall be deemed to
include, for purposes of this Section 8(d), any legal or other expenses
reasonably incurred by such indemnified party in connection with investigating
or defending any such action or claim. Notwithstanding the provisions
of this Section 8(d), no Underwriter shall be required to contribute any amount
in excess of the amount by which the net proceeds from the sale of the Shares
underwritten by it exceeds the amount of any damages that such Underwriter has
otherwise paid or become liable to pay by reason of any untrue or alleged untrue
statement or omission or alleged omission. No person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. The Underwriters’
obligations to contribute as provided in this Section 8(d) are several in
proportion to their respective underwriting obligations and not
joint.
(e) The
Underwriters severally confirm and the Company acknowledges and agrees that the
statements regarding delivery of Shares by the Underwriters set forth on the
cover page of, and the concession figure and the paragraphs relating to
stabilization, short positions and penalty bids and passive market making by the
Underwriters appearing under the caption “Underwriting” in, the most recent
Preliminary Prospectus and the Prospectus are correct and constitute the only
information concerning such Underwriters furnished in writing to the Company by
or on behalf of the Underwriters specifically for inclusion in any Preliminary
Prospectus, the Registration Statement, the Prospectus, any Issuer Free Writing
Prospectus or in any amendment or supplement thereto or in any Non-Prospectus
Road Show.
25
9.
Defaulting
Underwriters. If, on any Delivery Date, any Underwriter
defaults in the performance of its obligations under this Agreement, the
remaining non-defaulting Underwriters shall be obligated to purchase the Shares
that the defaulting Underwriter agreed but failed to purchase on such Delivery
Date in the respective proportions which the number of the Firm Shares set forth
opposite the name of each remaining non-defaulting Underwriter in Schedule 1 hereto
bears to the total number of the Firm Shares set forth opposite the names of all
the remaining non-defaulting Underwriters in Schedule 1 hereto;
provided, however, that the remaining
non-defaulting Underwriters shall not be obligated to purchase any of the Shares
on such Delivery Date if the total number of the Shares that the defaulting
Underwriter or Underwriters agreed but failed to purchase on such date exceeds
9.09% of the total number of the Shares to be purchased on such Delivery Date,
and any remaining non-defaulting Underwriter shall not be obligated to purchase
more than 110% of the number of the Shares that it agreed to purchase on such
Delivery Date pursuant to the terms of Section 2. If the foregoing
maximums are exceeded, the remaining non-defaulting Underwriters, or those other
underwriters satisfactory to the Representative who so agrees, shall have the
right, but shall not be obligated, to purchase, in such proportion as may be
agreed upon among them, all the Shares to be purchased on such Delivery
Date. If the remaining Underwriters or other underwriters
satisfactory to the Representative do not elect to purchase the Shares that the
defaulting Underwriter or Underwriters agreed but failed to purchase on such
Delivery Date, this Agreement (or, with respect to any Option Shares Delivery
Date, the obligation of the Underwriters to purchase, and of the Company to
sell, the Option Shares) shall terminate without liability on the part of any
non-defaulting Underwriter or the Company, except that the Company will continue
to be liable for the payment of expenses to the extent set forth in Sections 6
and 11. As used in this Agreement, the term “Underwriter” includes,
for all purposes of this Agreement unless the context requires otherwise, any
party not listed in Schedule 1 hereto
that, pursuant to this Section 9, purchases Shares that a defaulting Underwriter
agreed but failed to purchase.
Nothing
contained herein shall relieve a defaulting Underwriter of any liability it may
have to the Company for damages caused by its default. If other
Underwriters are obligated or agree to purchase the Shares of a defaulting or
withdrawing Underwriter, either the Representative or the Company may postpone
the Delivery Date for up to seven full business days in order to effect any
changes that in the opinion of counsel for the Company or counsel for the
Underwriters may be necessary in the Registration Statement, the Prospectus or
in any other document or arrangement.
10. Termination. The
obligations of the Underwriters hereunder may be terminated by the
Representative by notice given to and received by the Company prior to delivery
of and payment for the Firm Shares if, prior to that time, any of the events
described in Sections 7(k) and 7(l) shall have occurred or if the Underwriters
shall decline to purchase the Shares for any reason permitted under this
Agreement.
11. Reimbursement of Underwriters’
Expenses. If the Company shall fail to tender the Shares
for delivery to the Underwriters for any reason or (b) the Underwriters shall
decline to purchase the Shares for any reason permitted under this Agreement,
the Company will reimburse the Underwriters for all reasonable out-of-pocket
expenses (including fees and disbursements of counsel) incurred by the
Underwriters in connection with this Agreement and the proposed purchase of the
Shares, and upon demand the Company shall pay the full amount thereof to the
Representative. If this Agreement is terminated pursuant to Section 9
by reason of the default of one or more Underwriters, the Company shall not be
obligated to reimburse any defaulting Underwriter on account of those
expenses.
26
12. Research Analyst Independence.
The Company acknowledges that the Underwriters’ research analysts and
research departments are required to be independent from their respective
investment banking divisions and are subject to certain regulations and internal
policies, and that such Underwriters’ research analysts may hold views and make
statements or investment recommendations and/or publish research reports with
respect to the Company and/or the offering that differ from the views of their
respective investment banking divisions. The Company hereby waives
and releases, to the fullest extent permitted by law, any claims that the
Company may have against the Underwriters with respect to any conflict of
interest that may arise from the fact that the views expressed by their
independent research analysts and research departments may be different from or
inconsistent with the views or advice communicated to the Company by such
Underwriters’ investment banking divisions. The Company acknowledges
that each of the Underwriters is a full service securities firm and as such from
time to time, subject to applicable securities laws, may effect transactions for
its own account or the account of its customers and hold long or short positions
in debt or equity securities of the companies that may be the subject of the
transactions contemplated by this Agreement.
13. No Fiduciary
Duty. The Company acknowledges and agrees that in connection
with this offering, sale of the Shares or any other services the Underwriters
may be deemed to be providing hereunder, notwithstanding any preexisting
relationship, advisory or otherwise, between the parties or any oral
representations or assurances previously or subsequently made by the
Underwriters: (i) no fiduciary or agency relationship between the
Company and any other person, on the one hand, and the Underwriters, on the
other, exists; (ii) the Underwriters are not acting as advisors, expert or
otherwise, to the Company, including, without limitation, with respect to the
determination of the public offering price of the Shares, and such relationship
between the Company, on the one hand, and the Underwriters, on the other, is
entirely and solely commercial, based on arm’s-length negotiations; (iii) any
duties and obligations that the Underwriters may have to the Company shall be
limited to those duties and obligations specifically stated herein; and (iv) the
Underwriters and their respective affiliates may have interests that differ from
those of the Company. The Company hereby waives any claims that the
Company may have against the Underwriters with respect to any breach of
fiduciary duty in connection with this offering.
14. Notices,
Etc. All statements, requests, notices and agreements
hereunder shall be in writing, and:
(a) if
to the Underwriters, shall be delivered or sent by mail or facsimile
transmission to Barclays Capital Inc., 000 Xxxxxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx
00000, Attention: Syndicate Registration (Fax: 000-000-0000), with a
copy, in the case of any notice pursuant to Section 8(c), to the Director of
Litigation, Office of the General Counsel, Barclays Capital Inc., 000 Xxxxxxx
Xxxxxx, Xxx Xxxx, Xxx Xxxx 00000; and
(b) if
to the Company, shall be delivered or sent by mail or facsimile transmission to
First Financial Bancorp, 0000 Xxxxx Xxxx, Xxxxx 0000, Xxxxxxxxxx, Xxxx 00000,
Attention: Xxxxxxx X. Xxxxxxxx (Fax: 000-000-0000), with a copy to
Squire, Xxxxxxx & Xxxxxxx L.L.P., 000 Xxxx 0xx Xxxxxx, Xxxxx 0000,
Xxxxxxxxxx, Xxxx 00000, Attention: Xxxxx X. Xxxxxxx (Fax:
000-000-0000).
Any such
statements, requests, notices or agreements shall take effect at the time of
receipt thereof. The Company shall be entitled to act and rely upon
any request, consent, notice or agreement given or made on behalf of the
Underwriters by Barclays Capital Inc.
27
15. Persons Entitled to Benefit of
Agreement. This Agreement shall inure to the benefit of and be
binding upon the Underwriters, the Company, and their respective
successors. This Agreement and the terms and provisions hereof are
for the sole benefit of only those persons, except that (A) the representations,
warranties, indemnities and agreements of the Company contained in this
Agreement shall also be deemed to be for the benefit of the directors, officers
and employees of the Underwriters and each person or persons, if any, who
control any Underwriter within the meaning of Section 15 of the Securities
Act and (B) the indemnity agreement of the Underwriters contained in
Section 8(b) of this Agreement shall be deemed to be for the benefit of the
directors of the Company, the officers of the Company who have signed the
Registration Statement and any person controlling the Company within the meaning
of Section 15 of the Securities Act. Nothing in this Agreement
is intended or shall be construed to give any person, other than the persons
referred to in this Section 15, any legal or equitable right, remedy or claim
under or in respect of this Agreement or any provision contained
herein.
16. Survival. The
respective indemnities, representations, warranties and agreements of the
Company and the Underwriters contained in this Agreement or made by or on behalf
of them, respectively, pursuant to this Agreement, shall survive the delivery of
and payment for the Shares and shall remain in full force and effect, regardless
of any investigation made by or on behalf of any of them or any person
controlling any of them.
17. Definition of the Terms “Business
Day” and “Subsidiary”. For purposes of this Agreement,
(a) “business day” means
each Monday, Tuesday, Wednesday, Thursday or Friday that is not a day on which
banking institutions in New York are generally authorized or obligated by law or
executive order to close and (b) “subsidiary” has the meaning
set forth in Rule 405.
18. Governing
Law. This
Agreement shall be governed by and construed in accordance with the laws of the
State of New York.
19. Counterparts. This
Agreement may be executed in one or more counterparts and, if executed in more
than one counterpart, the executed counterparts shall each be deemed to be an
original but all such counterparts shall together constitute one and the same
instrument.
20. Headings. The
headings herein are inserted for convenience of reference only and are not
intended to be part of, or to affect the meaning or interpretation of, this
Agreement.
28
If the
foregoing correctly sets forth the agreement between the Company and the
Underwriters, please indicate your acceptance in the space provided for that
purpose below.
Very
truly yours,
|
|||
First
Financial Bancorp.
|
|||
By:
|
/s/ Xxxxxx X. Xxxxx
|
||
Name:
Xxxxxx X. Xxxxx
|
|||
Title:
President & CEO
|
29
Accepted:
|
||
Barclays
Capital Inc.
|
||
For
itself and as Representative
|
||
of
the several Underwriters named
|
||
in
Schedule 1 hereto
|
||
By:
|
/s/ Xxxx Xxxxxxxx
|
|
Authorized
Representative
|
30
SCHEDULE
1
Underwriters
|
Number of
Firm Shares
|
Number of
Option Shares
|
||||||
Barclays
Capital Inc.
|
3,368,520 | 454,750 | ||||||
RBC
Capital Markets Corporation
|
1,543,905 | 208,427 | ||||||
Xxxxxxx
Xxxxx & Associates, Inc.
|
701,775 | 94,740 | ||||||
Total
|
5,614,200 | 757,917 |
SCHEDULE
2
PERSONS
DELIVERING LOCK-UP AGREEMENTS
Directors
X.
Xxxxxxxxx Ach
Xxxxxx X.
Xxxxx, Xx.
Xxxx X.
Collar
Xxxxxxx
X. Xxxxxxxx
Xxxxx
Xxxxxx
Xxxxx X.
Xxxxx
Xxxxxxx
X. Xxxxxx
Xxxxxxx
X. Xxxxxxxxx
Officers
Xxxxxxx
Xxxxxxxxxxx
Xxxxxx X.
Xxxxx
Xxxxxxx
X. Xxxxxxxx
X.
Xxxxxxxx Xxxx
Xxxxxxx
X. Xxxxxxxxx
Xxxxxx X.
Xxxxxx
Xxxxxxx
X. Xxxxxxxxx
SCHEDULE
3
ORALLY
CONVEYED PRICING INFORMATION
1. $15.14
per share
2. 5,614,200
shares
SCHEDULE
4
SIGNIFICANT
SUBSIDIARIES
1. First
Financial Bank, National Association, organized as a national banking
association under the laws of the United States
2. First
Financial Capital Advisors, LLC, organized as a limited liability company under
the laws of the state of Ohio
3. First
Financial (OH) Statutory Trust II, created under the laws of the state of
Delaware
4. FFBC
Capco Inc., incorporated in the state of Indiana
5. MXG,
Inc., incorporated in the state of Ohio
Exhibit
A
LOCK-UP
AGREEMENT
Barclays
Capital Inc.
As
Representative of the several
Underwriters
c/o
Barclays Capital Inc.
000
Xxxxxxx Xxxxxx
Xxx Xxxx,
Xxx Xxxx 00000
Ladies
and Gentlemen:
The
undersigned understands that you, as representative (the “Representative”), propose to
enter into an Underwriting Agreement (the “Underwriting Agreement”), on
behalf of the several Underwriters named in Schedule 1 to such Underwriting
Agreement (collectively, the “Underwriters”) with First
Financial Bancorp., an Ohio corporation (the “Company”), providing for a
public offering (the “Offering”) of the Company’s
common shares, without par value (the “Common Shares”), pursuant to a
Registration Statement on Form S-3 that has been filed with the Securities and
Exchange Commission (the “SEC”).
In
consideration of the agreement by the Underwriters to offer and sell the Common
Shares in the Offering, and for other good and valuable consideration, the
undersigned hereby irrevocably agrees that (other than as set forth below),
without the prior written consent of the Representative, on behalf of the
Underwriters, the undersigned will not, directly or indirectly, (1) offer for
sale, sell, pledge, or otherwise dispose of (or enter into any transaction or
device that is designed to, or could be expected to, result in the disposition
by any person at any time in the future of) any Common Shares (including,
without limitation, Common Shares that may be deemed to be beneficially owned by
the undersigned in accordance with the rules and regulations of the SEC and
Common Shares that may be issued upon exercise of any options or warrants) or
securities convertible into or exercisable or exchangeable for Common Shares
(collectively, the “Undersigned’s Shares”), (2)
enter into any swap or other derivatives transaction that transfers to another,
in whole or in part, any of the economic benefits or risks of ownership of
Common Shares, whether any such transaction described in clause (1) or (2) above
is to be settled by delivery of Common Shares or other securities, in cash or
otherwise, (3)
make any demand for or exercise any right or cause to be filed a registration
statement, including any amendments thereto, with respect to the registration of
Common Shares or securities convertible into or exercisable or exchangeable for
Common Shares or any other securities of the Company, or (4) publicly disclose
the intention to do any of the foregoing, for a period commencing on the date of
the preliminary prospectus supplement relating to the Offering and continuing to
and including the date 90 days after such date (such 90-day period, the “Lock-Up
Period”).
Notwithstanding the foregoing, the
undersigned may (1) transfer the Undersigned’s Shares as a bona
fide gift or gifts,
provided that the donee or donees thereof agree to be bound in writing by the
restrictions set forth herein, (2) transfer the Undersigned’s Shares to any
trust, corporation, partnership or other entity owned or existing for the direct
or indirect benefit of the undersigned or the immediate family of the
undersigned, provided that the donee or donees thereof agree to be bound in
writing by the restrictions set forth herein, and provided further that any such
transfer shall not involve a disposition for value, (3) sell or make deemed sales of Common
Shares to the Company pursuant to net exercises or cashless exercises of options
outstanding on the date hereof, to the extent that such Common
Shares are not subsequently sold by the Company on the open market for a period
commencing on the date of the Underwriting Agreement and ending 90 days after
the date of the Underwriting Agreement, (4) transfer the
Undersigned’s Shares pursuant to any Rule 10b5-1 trading plan in existence prior
to the date of the preliminary prospectus supplement relating to the
Offering, (5) transfer the
Undersigned's Shares for payment of taxes required to be paid upon the vesting
of restricted Common Shares, or (6) transfer the Undersigned’s Shares by
operation of law, such as pursuant to the rules of intestate succession or
statutes governing the effects of a merger, provided that prior to the transfer,
the transferee agrees to be bound in writing by the restrictions set forth
herein. For purposes of
this Lock-Up Agreement, “immediate family” shall mean any relationship by blood,
marriage or adoption, not more remote than first cousin.
Notwithstanding
the foregoing, if (1) during the last 17 days of the Lock-Up Period, the Company
issues an earnings release or material news or a material event relating to the
Company occurs or (2) prior to the expiration of the Lock-Up Period, the Company
announces that it will release earnings results during the 16-day period
beginning on the last day of the Lock-Up Period, then the restrictions imposed
by this Lock-Up Agreement shall continue to apply until the expiration of the
18-day period beginning on the issuance of the earnings release or the
announcement of the material news or the occurrence of the material event,
unless the Representative waives such extension in writing. The
undersigned hereby further agrees that, prior to engaging in any transaction or
taking any other action that is subject to the terms of this Lock-Up Agreement
during the period from the date of this Lock-Up Agreement to and including the
34th
day following the expiration of the Lock-Up Period, it will give notice thereof
to the Company and will not consummate such transaction or take any such action
unless it has received written confirmation from the Company that the Lock-Up
Period (as such may have been extended pursuant to this paragraph) has
expired.
In
furtherance of the foregoing, the Company and its transfer agent are hereby
authorized to decline to make any transfer of securities if such transfer would
constitute a violation or breach of this Lock-Up Agreement.
It is
understood that, if the Company notifies the Underwriters that it does not
intend to proceed with the Offering, if the Underwriting Agreement does not
become effective, or if the Underwriting Agreement (other than the provisions
thereof which survive termination) shall terminate or be terminated prior to
payment for and delivery of the Common Shares to be sold thereunder, the
undersigned will be released automatically and immediately from all obligations
under this Lock-Up Agreement.
2
The
undersigned understands that the Company and the Underwriters will proceed with the Offering
in reliance on this Lock-Up Agreement.
This
Lock-Up Agreement shall be governed by and construed in accordance with the laws
of the State of New York.
[Signature
page follows]
3
The
undersigned hereby represents and warrants that the undersigned has full power
and authority to enter into this Lock-Up Agreement and that, upon request, the
undersigned will execute any additional documents necessary in connection with
the enforcement hereof. Any obligations of the undersigned shall be
binding upon the heirs, personal representatives, successors and assigns of the
undersigned.
Very
truly yours,
|
||
By:
|
||
Name:
|
||
Title:
|
Dated: _______________
4
EXHIBIT
B-1
FORM OF OPINION OF SQUIRE,
XXXXXXX & XXXXXXX L.L.P.1
|
·
|
The
Company is validly existing as a corporation in good standing under the
laws of the State of Ohio.
|
|
·
|
The
Company is duly registered as a bank holding company under the Bank
Holding Company Act of 1956, as
amended.
|
|
·
|
The
Company has the corporate power and authority to enter into the
Underwriting Agreement and to perform its obligations
thereunder.
|
|
·
|
The
statements set forth in the Pricing Disclosure Package and the Prospectus
under the caption “Certain U.S. Federal Income and Estate Tax
Consequences to Non-U.S. Holders,” insofar as they purport to summarize
the material U.S. federal tax consequences of the purchase, ownership, and
disposition of the Common Shares to the holders thereof described therein
under the U.S. Internal Revenue Code of 1986 and the regulations or
administrative rulings thereunder, are accurate, complete, and fair
summaries of the matters described therein in all material
respects. All such statements are based upon current law which
is subject to change, possibly with retroactive effect. Further, there can
be no assurance that the Internal Revenue Service or a court will not take
a contrary position.
|
|
·
|
The
execution and delivery by the Company of the Underwriting Agreement have
been duly authorized by all necessary corporate action on the part of the
Company, and the consummation of the transactions contemplated therein and
in the Pricing Disclosure Package and the Prospectus (including the
issuance and sale of the Common Shares) do not and the performance by the
Company of its obligations under the Underwriting Agreement will not (i)
require any consent, approval, license or exemption by, order or
authorization of, or filing, recording or registration (each, a “Consent”)
by the Company with any state or federal governmental authority, except
such as have been made or obtained under the Securities Act, (ii) violate
articles of incorporation or regulations of the Company, or (iii) violate
any Ohio, New York, or federal statute, rule or regulation, or, to the
best of our knowledge, any court order, judgment or decree to which the
Company is subject.
|
|
·
|
The Company has an authorized
capitalization as set forth in the Pricing Disclosure Package and the
Prospectus.
|
Exhibit
B-1-1
|
·
|
The issuance and sale of the
Common Shares pursuant to the Underwriting Agreement have been duly
authorized, and upon payment of the consideration therefor specified in
the Underwriting Agreement, the Common Shares will be validly issued,
fully paid and
nonassessable.
|
|
·
|
No shareholder of the Company or
any other person has any preemptive right, right of first refusal or other
similar right to subscribe for or purchase securities of the Company
arising (i) by operation of the articles of incorporation or the
regulations or the General Corporation Law of the State of Ohio or (ii) to
our best knowledge,
otherwise.
|
|
·
|
The
statements in the Pricing Disclosure Package and the Prospectus under the
captions “Benefit Plan Investor Considerations,” “Description of the
Capital Shares and the Warrant” and “Description of Common Shares,”
insofar as such statements contain descriptions of laws, rules or
regulations, and insofar as they describe the terms of agreements or the
articles of incorporation or regulations of the Company, are correct in
all material respects.
|
|
·
|
The
Company is not required, and as a result of the issuance of the Common
Shares as contemplated in the Underwriting Agreement and the application
of the proceeds therefrom as described in the Pricing Disclosure Package
and the Prospectus will not be required, to register as an “investment
company” as defined in the Investment Company Act of 1940, as
amended.
|
|
·
|
Each document filed pursuant to
the Exchange Act (other than the financial statements and supporting
schedules included therein, as to which no opinion need be rendered) and
incorporated or deemed to be incorporated by reference in the Prospectus
complied when so filed as to form in all material respects with the
Exchange Act.
|
|
·
|
We confirm to you that: (i)
on the basis of the information that we gained in the course of performing
the services referred to above, nothing came to our attention that caused
us to believe that (a) the Registration Statement, as of February ●, 2010,
contained an untrue statement of a material fact or omitted to state a
material fact required to be stated therein or necessary to make the
statements therein not misleading, (b) the Pricing Disclosure Package, at
the Applicable Time, contained an untrue statement of a material fact or
omitted to state a material fact necessary to make the statements therein,
in light of the circumstances under which they were made, not misleading,
or (c) the Prospectus, as of its date, contained any untrue statement of a
material fact or omitted to state any material fact necessary to make the
statements therein, in light of the circumstances under which they were
made, not misleading, and (ii) nothing came to our attention in the course
of the procedures described in the Ÿ paragraph above
that caused us to believe that the Prospectus, as of the date and time of
delivery of this letter, contains any untrue statement of a material fact
or omits to state any material fact necessary to make the statements
therein, in light of the circumstances under which they were made, not
misleading; provided,
however, that we do not assume any responsibility for the accuracy,
completeness or fairness of the statements contained in the Registration
Statement, the Pricing Disclosure Package or the Prospectus and we do not
express any belief as to the financial statements and related notes,
financial statement schedules or other financial data derived from
accounting records contained in or omitted from the Registration
Statement, the Pricing Disclosure Package or the Prospectus. In
the first sentence of this paragraph, “attention” refers to the conscious
awareness of each of the lawyers in our firm who participated in the
preparation of the Registration Statement, the Pricing Disclosure Package
or the Prospectus; and “believe” refers to the actual, subjective, good
faith belief of each of those lawyers. In addition, we express
no opinion or belief as to the conveyance of the Pricing Disclosure
Package or the information contained therein to
investors.
|
Exhibit
X-0-0
XXXXXXX
X-0
FORM OF OPINION OF XXXXXXX
X. GEHLMANN2
|
·
|
The
Company has been duly incorporated and is validly existing as a
corporation in good standing under the laws of the State of
Ohio.
|
|
·
|
The
Company is duly qualified as a foreign corporation to transact business
and is in good standing in each jurisdiction in which such qualification
is required, whether by reason of the ownership or leasing of property or
the conduct of business, except where the failure so to qualify or to be
in good standing would not result in a Material Adverse
Effect.
|
|
·
|
The
Company has the corporate power and authority to own, lease and operate
its properties and to conduct its business as described in the Pricing
Disclosure Package and the
Prospectus.
|
|
·
|
The
consummation of the transactions contemplated in the Underwriting
Agreement, the Pricing Disclosure Package and the Prospectus (including
the issuance and sale of the Securities and the use of proceeds from the
sale of the Securities as described in the Pricing Disclosure Package and
the Prospectus under the caption “Use of Proceeds”) does not and the
performance by the Company of its obligations under the Underwriting
Agreement will not (i) conflict with any material provision of any
contract to which the Company is a party and has been filed or furnished
with the Commission or (ii) violate any court order, judgment or decree to
which the Company is subject.
|
|
·
|
All
of the Company’s outstanding Common Shares have been duly authorized, and
validly issued, and are fully paid and
non-assessable.
|
|
·
|
Based
solely upon a review on X, 0000 of
certificates representing outstanding capital stock or other equity or
ownership interests of, and stock, ownership or other equity transfer
records for, each Significant Subsidiary, all of the issued and
outstanding capital stock or other equity interests of each Significant
Subsidiary is owned, directly by, or through other subsidiaries of, the
Company. Except as described in the Pricing Disclosure Package
and the Prospectus, (i) there are no outstanding rights (contractual or
otherwise), warrants or options to acquire, or instruments convertible
into or exchangeable for, or agreements or understandings with respect to
the sale or issuance of, any shares of capital stock of or other equity
interest in the Company; and (ii) there are no contracts, agreements or
understandings between the Company and any person granting such person the
right to require the Company to file a registration statement under the
Securities Act or otherwise register any securities of the Company owned
or to be owned by such person, other than pursuant to the Company’s
dividend reinvestment plan.
|
2 Xxxxxxxx
& Xxxxxxxx LLP may rely upon the opinion of Xxxxxxx X. Xxxxxxxx for its
opinions to the Underwriters as to matters involving Ohio
laws.
Exhibit
B-2-1
|
·
|
Except
as disclosed in the Pricing Disclosure Package and Prospectus, (i) neither
the Company nor any Significant Subsidiary is in violation of its articles
of incorporation or regulations, and (ii) no default by the Company or any
Significant Subsidiary of the Company exists in the due performance or
observance of any obligation, agreement, covenant or condition contained
in any contract, indenture, mortgage, loan agreement, note, lease or other
agreement or instrument that is described or referred to in the Pricing
Disclosure Package or the Prospectus, except for such defaults which,
individually or in the aggregate, would not have a Material Adverse
Effect.
|
|
·
|
Each
Significant Subsidiary of the Company, other than First Financial Bank,
N.A., has been duly organized and is validly existing as a corporation,
limited partnership, trust company or limited liability company in good
standing under the laws of the jurisdiction of its organization, has the
power and authority to own, lease and operate its properties and conduct
its business as described in the Pricing Disclosure Package and the
Prospectus, and is duly qualified as a foreign corporation or entity to
transact business and is in good standing in each jurisdiction in which
such qualification is required, whether by reason of the ownership or
leasing of property or the conduct of business, except where the failure
to qualify as a foreign corporation or entity to transact business would
not result in a Material Adverse
Effect.
|
|
·
|
First
Financial Bank, N.A., has been duly organized and is validly existing as a
national banking association, with corporate power and authority to own or
lease its properties and conduct its business as described in the Pricing
Disclosure Package and the
Prospectus.
|
|
·
|
Except
as disclosed in the Pricing Disclosure Package and the Prospectus, no
Significant Subsidiary of the Company is prohibited or restricted,
directly or indirectly, from paying dividends to the Company, or from
making any other distribution with respect to such Significant
Subsidiary’s equity securities or from repaying to the Company or any
other Significant Subsidiary of the Company any amounts that may from time
to time become due under any loan or advances to such Significant
Subsidiary from the Company or from transferring any property or assets to
the Company or to any other Significant
Subsidiary.
|
|
·
|
Except
as described in the Pricing Disclosure Package and the Prospectus, there
is no action, suit, proceeding, inquiry or investigation before or brought
by any court or governmental agency or body, domestic or foreign, now
pending, or, to the best of my knowledge, threatened, against or affecting
the Company or any subsidiary, which could, individually or in the
aggregate, reasonably be expected to result in a Material Adverse
Effect.
|
Exhibit
B-2-2
Exhibit
C
FIRST
FINANCIAL BANCORP
CHIEF FINANCIAL OFFICER’S
CERTIFICATE
___________,
2010
I, J.
Xxxxxxxx Xxxx, do hereby certify that I am the Chief Financial Officer of First
Financial Bancorp (the “Company”) and, in my
capacity as such, and based upon an examination of the Company’s financial
records and schedules undertaken by myself or members of my staff who are
responsible for the Company’s financial and accounting matters, do hereby
certify that:
|
1.
|
I
am providing this certificate in connection with the offering (the “Offering”) by
the Company of ● common shares (the “Common Shares”)
pursuant to an underwriting agreement, dated January 27, 2010, between the
Company and Barclays Capital Inc., as representative of the several
underwriters named therein, as described in the Registration Statement on
Form S-3 (No. 333-153751) filed with the Securities and Exchange
Commission (the “SEC”) under the
Securities Act of 1933, as amended (the “Securities
Act”), and the prospectus, dated May 1, 2009, as supplemented by
the preliminary prospectus supplement, dated January 26, 2010 (the “Prospectus
Supplement”), related to the Common Shares, (collectively, the
“Registration
Statement”).
|
|
2.
|
I
am familiar with the accounting, operations and records systems of the
Company and its consolidated subsidiaries. I have (i) read the
Registration Statement and (ii) supervised the compilation of and reviewed
the information set forth in (A) Exhibit 99.2 to the Company’s Current
Report on Form 8-K, which was filed with the SEC on January 26, 2010 under
accession number 0001144204-10-003617 and incorporated by reference in the
Prospectus Supplement and (B) the Prospectus Supplement under the captions
“Prospectus Supplement Summary — Recent Developments — Fourth Quarter and
Full Year 2009 Results from Operations” and “Prospectus Supplement Summary
— Recent Developments — Summary Historical Financial Information” and
“Capitalization”, collectively (the “2009 Financial
Information”).
|
|
3.
|
The
unaudited consolidated financial information of the Company as of and for
the three-month and twelve-month periods ended December 31, 2009 included
in the 2009 Financial Information (i) either (A) has been prepared in
conformity with accounting principles generally accepted in the United
States of America (except for the failure to include footnotes with such
consolidated financial information) consistently applied with prior
periods, (B) in the case of any ‘Non-GAAP Financial Measure” (as defined
in Rule 101(a)(1) of Regulation G promulgated under the Securities Act)
included in the 2009 Financial Information, is presented in accordance
with the requirements of Rules 100(a) and 100(b) of Regulation G, or (C)
is not a “Non-GAAP Financial Measure” (as defined in Rule 101(a)(1) of
Regulation G), and (ii) gives a true and fair view of the financial
condition and results of operations of the Company and its consolidated
subsidiaries as of that date and for those
periods.
|
Exhibit
C-1
|
4.
|
Nothing
has come to my attention that causes me to believe that the information
contained in the 2009 Financial Information is not true, correct and
accurate in all material respects, as of the date of the 2009 Financial
Information and as of the date
hereof.
|
Exhibit
C-2
IN
WITNESS WHEREOF, the undersigned has executed and delivered this chief financial
officer’s certificate on behalf of the Company as of the date first written
above.
By
|
||
Name:
|
J.
Xxxxxxxx Xxxx
|
|
Title:
|
Chief
Financial
Officer
|
Exhibit
C-3